SS-31 (Elamipretide)

SS-31 (Elamipretide) is a cutting-edge peptide that targets the "power plants" of your cells — the mitochondria. Unlike typical antioxidants that mop up damage after it happens, SS-31 prevents damage at the source. **Why mitochondria matter:** Mitochondria produce over 90% of your cellular energy. When they dysfunction — which happens increasingly with age and disease — cells can't work properly, leading to fatigue, organ decline, and accelerated aging. **How SS-31 works:** SS-31 concentrates in the inner mitochondrial membrane where it stabilizes cardiolipin, a crucial molecule for energy production. This improves efficiency and dramatically reduces the "exhaust" (reactive oxygen species) that damages cells. **What the research shows:** • Enhances cellular energy production (ATP) • Protects heart, kidney, and brain tissue in injury models • May improve exercise capacity and reduce fatigue • Studied in clinical trials for mitochondrial diseases and heart failure • Could slow age-related functional decline **Clinical development:** Currently being studied for primary mitochondrial myopathy, heart failure, and age-related conditions. **Important to know:** SS-31 is not yet FDA-approved. Clinical trials are ongoing for various conditions involving mitochondrial dysfunction. --- **Sources:** Szeto HH, et al. (2014) British Journal of Pharmacology | Karaa A, et al. (2018) Neurology | Sabbah HN, et al. (2016) Circulation: Heart Failure

Approval is accelerated (requires confirmatory trials); trials in heart failure and mitochondrial myopathy showed mixed results; long-term outcomes data are limited; use for general 'mitochondrial health' or anti-aging is off-label and unsupported.

Small mitochondrial-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); administered subcutaneously (Forzinity); selectively partitions into the inner mitochondrial membrane, binds cardiolipin, stabilizes cristae, and improves electron transport efficiency while reducing ROS. Half-life is short, requiring frequent dosing.